

# Quality by Design in API Manufacturing

How to connect critical quality attributes with critical process parameters

#### **SPEAKERS:**



Lígia Brás Hovione, Portugal



Horn Pharmaceutical Consulting, Germany



Francois Vandeweyer Janssen Pharmaceutica, Belgium



Elmar Wenzel
Freelance Consultant,
Germany



#### 11 – 12 October 2017, Heidelberg, Germany

#### **HIGHLIGHTS:**

- Key elements and general framework of QbD for APIs
- A risk-based approach to developing a control strategy
- How to identify and control Critical Quality Attributes in API synthesis
- Dossier requirements regarding information on the API manufacturing process
- Process Evaluation and Design Space
- Application of PAT in the API manufacturing
- Different types/elements of a control strategy



#### Quality by Design in API Manufacturing

#### 11 – 12 October 2017, Heidelberg, Germany

#### **Objectives**

During this course the principles and key aspects of Quality by Design will be discussed. You will learn

- How to identify Critical Quality Attributes
- How to design an effective risk based control strategy
- How to provide QbD related information in a regulatory submission
- How Process Analytical Technology can be applied as part of a control strategy

In an interactive workshop provides the opportunity to elaborate criticality analyses for various API syntheses.

#### **Background**

In many cases the synthesis of small molecule APIs is achieved by using multiple intermediates which themselves are produced using different processes. To ensure the API manufacturing process consistently delivers an API meeting its specifications each of these processes needs to be robust.

The Quality by Design approach aims to scientifically determine product and process characteristics derived from criteria set after analysis of the intended drug application.

These product characteristics, the so called critical quality attributes (CQAs), must be identified and in the next step the critical process parameters (CPPs) have to be determined.

Suitable approaches to identify these parameters are design of experiments (DOE) or general risk assessments e.g. FMEA. When linked to each other the CQAs and CPPs define the range within the process is considered to be robust.

This has to be demonstrated by a compilation of the relevant information in the application dossier.

#### **Target Audience**

This course is designed for all persons which are involved in the manufacture of APIs especially in process development, process validation, scale-up and transfer and CMC dossier preparation. Furthermore, the seminar will be of interest to personnel from quality assurance, regulatory affairs both from API and pharmaceutical companies and to contract manufacturers.

#### **Programme**

#### General framework and key elements of QbD for APIs

- background and potential strategies
- What is it all about?
- What are the benefits?
- When and how should you use it?
- Practical examples with typical points of discussion

## How to identify and control Critical Quality Attributes (CQAs) in API synthesis – a risk-based approach to developing a control strategy

- Severity assessment of quality attributes
- Impact levels for critical process parameters (CPPs) and critical material attributes (CMAs)
- Considerations for the API Starting material
- Design of an effective risk-based control strategy
- Examples

## How to provide information on the development of the API manufacturing process – dossier requirements

- What should be done at which stage?
- Which information is relevant for the dossier?
- What are the key-points to be considered for APIs (NCE/Biotech) and their formulations
- Typical questions from Authorities

#### **Process Evaluation and Design Space**

- Changing Validation Approach
- Validation Life Cycle
- Design Space Concept

#### Application of PAT in the API industry

- PAT at development stages of a QbD-based development
- PAT as part of the Control Strategy in a GMP environment
- Practical examples of PAT implementations at a commercial scale in a GMP environment

#### **Control strategies - Case studies and examples**

- HA definitions
- Why and When is a control strategy needed
- Different types/elements of a control strategy
- Practical examples

#### Workshop

### Identification and classification of CQAs in API synthesis

In this workshop delegates will elaborate criticality analyses of different APIs. As part of this analyses critical quality attributes and critical process steps within the synthesis of the APIs will be identified.



#### **Social Event**



In the evening of the first course day, you are cordially invited to a dinner. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere

#### Heidelberg - Optimal Accessibility via Frankfurt

TLS:

http://www.tls-heidelberg.de

Lufthansa Bus:

http://www.transcontinental-group.com/en/frankfurt-airport-shuttles

PMI:

http://www.pmj-fahrservice.de

#### Train:

You can get on the train directly at the airport. Trains leave up to two times per hour and it takes less than one hour to get to Heidelberg. http://www.bahn.de

#### **Speakers**



#### Dr Lígia Brás

Hovione FarmaCiencia SA, Portugal Lígia Brás, PhD, is a PAT specialist in the Operational Excellence group at Hovione (Loures, Portugal), a company with more than 50 years' experience in API development and

compliance manufacture. She received both her degree in Biological Engineering and her PhD in Biotechnology from the Technical University of Lisbon, Portugal. She started working in chemometrics and PAT applications in academia in 2003. Currently, Lígia has been supporting Hovione teams on analytical technologies and statistical tools implementation to achieve manufacturing processes' efficiency targets and improve operational knowledge.



#### Dr Hiltrud Horn

Horn Pharmaceutical Consulting, Germany
Dr Hiltrud Horn is managing director of
HORN PHARMACEUTICAL CONSULTING
with focus on CMC, GMP and Regulatory Affairs (EU and US). She started in pharma in-

dustry in 1990 and held several managerial positions within Hoffmann-La Roche in Basel and Knoll (now Abbott) in Ludwigshafen with global responsibility within QC / QA / Regulatory Affairs / Project Management / Medical Writing. She was consultant for the biotech and life science industry at Cap Gemini Ernst & Young prior to starting her own business more than 13 years ago. She is pharmacist with a Ph.D. and holds a Diploma in Pharmaceutical Medicine (Basel). Furthermore, she is specialised pharmacist for pharmaceutical analytics and for drug information.



Francois Vandeweyer

Janssen Pharmaceutica, Belgium
Francois Vandeweyer joined Janssen Pharmaceutica (part of Johnson & Johnson) in 1981 in chemical development. Until 1995 increasing responsibilities within the organisation mainly

in the Quality Control Unit. Starting from 1995 he joined the QA department. Several Senior Manager responsibilities. 2005 Sr Manager GMP Compliance Chemical Operations Belgium (sites Geel – Olen – Beerse). 2009 Director Global Compliance EMEA/AP for Johnson & Johnson.



#### Elmar Wenzel,

Freelance Consultant, Germany
Mr Wenzel was formerly head of API
production at the Plankstadt site of AstraZeneca, now Corden Pharma. He is now freelance consultant.

**Reservation Form:** CONCEPT HEIDELBERG P.O. Box 10 17 64 69007 Heidelberg Germany



**Reservation Form:** + 49 6221 84 44 34







Quality by Design in Drug Product Development, 10-11 October 2017, Heidelberg, Germany Quality by Design in API Manufacturing, 11-12 October 2017, Heidelberg, Germany

Ms

Ž

e, first name, surname

Reservation Form (Please complete in full)

If the bill-to-address deviates from the specifica-

tions on the right, please fill out here:

	国	13	<u>E</u>	Str
				CONCEPT HEIDELBERG P.O. Box 101764
				$\circ$

PO Number if applicabl E-Mail (please fill in) Department portant: Please indicate your company's VAT ID Number Fax eet/P.O. Box mpany

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidebley will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only seam on information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca\_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

ave to inform us in writing. The cancellation fee will then be lated according to the point of time at which we receive your age. In case you do not appear at the event writhout having need us, you will have to pay the full registration fee, even if you not madel the payment yet. Only after we have received your ent, you are entitled to participate in the conference (receipt of ent, will not be confirmed)! (As of January 2012)

you have t calculated message. I informed t have not n payment, y

structors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full retund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred tent to a cancellation, able without deductions within 10 days after receipt of invoice. In Important. This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part,

Phone

City

Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg

GERMANY

#### **Date**

Wednesday, 11 October 2017, 14.00 h - 18.00 h (Registration and coffee 13.30 h - 14.00 h) Thursday, 12 October 2017, 9.00 h - 15.15 h

#### Venue

Heidelberg Marriott Hotel Vangerowstrasse 16 69115 Heidelberg, Germany Phone +49 (0)6221 - 908 0 +49 (0)6221 - 908 698 info.heidelberg@marriott.com email

#### Fees (per delegate plus VAT)

ECA Members € 1,490 APIC Members € 1,590 Non-ECA Members € 1,690 EU GMP Inspectorates € 845

The conference fee is payable in advance after receipt of invoice and includes conference documentation, business lunch and dinner on the first day, lunch on the second day and all refreshments. VAT is reclaimable.

#### Would you like to save money?

If you book "Quality by Design in API manufacturing" AND "Quality by Design in Drug Product Development" simultaneously, the fee for EACH conference reduces as follows:

ECA Members € 1,290 APIC Members € 1,390 Non-ECA Members € 1,490 EU GMP Inspectorates € 745

#### Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

#### Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

#### **Conference Language**

The official conference language will be English.

#### **Organisation and Contact**

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG P.O. Box 10 17 64 69007 Heidelberg, Germany Phone +49-62 21/84 44-0 Fax +49-62 21/84 44 84 info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content:

Dr Gerhard Becker (Operations Director) at +49-62 21/84 44 65, or per e-mail at becker@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc.:

Mr Ronny Strohwald (Organisation Manager) at +49-62 21/84 44 51, or per e-mail at strohwald@concept-heidelberg.de

If you cannot attend the conference you have two options:

1. We are hapty to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing teses: Cancellation

- until cases: Cancellation

- until I weeks prior to the conference 10 %

- until I weeks prior to the conference 50 %

- within I week prior to the conference 10 %

- contrain week prior to the conference 10 %

CONCEPT HEIDELBRG reserves the right to change the materials, in-

wa/vers1/22022017